The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi Group21 - 22 October 2019, Boston, USA.
With a massive growth within the HPAPI market, manufacturers cannot afford to be complacent in terms of staff training, utilization of approved technology and blueprint accident plans. Straying away from the correct procedures can have a massive affect on your business and industry.

At the inaugural HPAPI USA conference, these issues will be discussed and give delegates the opportunity to hear from industry experts who will share their experiences and arm attendees with the safety strategies to implement into their organization.

Ayasha Ovals from Taro Pharmaceuticals will provide a keynote address on Day One of the conference, where she will give insights into emergency procedures for HPAPI disasters and how to manage an accident, including long term cost savings, managing risk, fail-safe procedure and forward planning.

Industrial hygiene and potent compound containment will be discussed by Joseph Grill, former Associate Director from Purdue Pharma, where he will share insights on common pitfalls in industrial hygiene, flexible containment and the potential of hastening R&D.

Sakari Consultants, President & Principle, Patricia Weidemanwill focus on training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management. She will also look at technological innovations for containment and transfer technologies, ensuring staff are sufficiently trained and ensure they understand the equipment they are utilising.

The programme with full speaker line-up is available to download at www.hpapi-usa.com

Plus, two HPAPI USA Post Conference Workshops will take place in Boston on October 23rd:

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics hosted byDr Janet Gould, Principal Toxicologist, SafeBridge Consultants and Charlyn Reihamn, Principle Occupational Health Consultant,SafeBridge Consultants

Workshop B: How to sell your containment project to management: financial justification for containment solutions hosted by DrDavid Eherts, Vice President Global EHS, Allergan Inc

For those interested, an early bird saving of $300 is available for conference tickets booked before Friday 28th June. Register online at www.hpapi-usa.com

Sponsoredby BSP Pharmaceuticals, LONZA, Minakem, SafeBridge Consultants

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 This email address is being protected from spambots. You need JavaScript enabled to view it.

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...